Alzheimer’s Treatment Needs More Than Amyloid Drugs
TL;DR: A 2026 review in Science China Life Sciences argued that Alzheimer’s treatment is moving toward biomarker-guided combinations that address amyloid, tau, APOE, immune state, vascular health, and aging biology. Key Findings Slowing decline is not restoring it: Amyloid antibodies modestly slow progression in early disease but do not reverse cognition — the gap that …
